HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
(Date:7/23/2014)... 23, 2014 “I believe that 70% of ... longtime spokesperson for Bragg Live Foods, whose products are sold ... opinion on the Sharon Kleyne Hour Power of Water radio ... the toxicity to big business farming, consumer demand and a ... Bragg Live Foods and daughter-in-law of Paul Bragg, who founded ...
(Date:7/23/2014)... Washington, DC’s long awaited Silver Line Metrorail will ... This expansion to the city’s current lines could translate ... area, located just outside the city. Not only will ... growth, but it will also expand the hotel options ... surrounding areas. , “We couldn’t be happier to have ...
(Date:7/23/2014)... On July 19 and 20, the HearStrong ... New York and New York Giants Health & Fitness Expo ... , The team, which included several hearing healthcare providers affiliated ... health screenings and answered any questions that attendees had about ... , Also sponsored by the NFL Players Association, HearStrong was ...
(Date:7/23/2014)... Il (PRWEB) July 23, 2014 ISI ... solutions, has released Infortel Speech Analytics, a ... solutions. , Infortel Speech Analytics gives users the ability ... and/or video recordings , as well as chat ... this solution may not be new, adding speech analytics ...
(Date:7/23/2014)... 23, 2014 Temecula Valley Southern ... Valley Southern California Wine Country artisan food and ... two nights genuinely nourishing. Savor like locals at ... and Vindemia wineries; EAT Marketplace, Palumbo’s Ristorante, Robin’s ... Olive Oil,” announced Kimberly Adams, president and CEO, ...
Breaking Medicine News(10 mins):Health News:U.S. Farms Toxic Says Health Food Pioneer on Sharon Kleyne Hour Power of Water 2Health News:Washington, DC’s Metrorail Expansion Opening this Week Changes the Capital City’s Landscape for Locals and Visitors Alike 2Health News:Washington, DC’s Metrorail Expansion Opening this Week Changes the Capital City’s Landscape for Locals and Visitors Alike 3Health News:Washington, DC’s Metrorail Expansion Opening this Week Changes the Capital City’s Landscape for Locals and Visitors Alike 4Health News:The HearStrong Foundation Provides Hearing Healthcare Awareness at the NBC 4 New York and New York Giants Health & Fitness Expo 2014 2Health News:ISI Telemanagement Solutions, Inc. Releases Infortel® Speech Analytics 2Health News:ISI Telemanagement Solutions, Inc. Releases Infortel® Speech Analytics 3Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 2Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 3Health News:12 Artisan Food and Wine Experiences in Temecula Valley Southern California Wine County 4
(Date:7/22/2014)... 2014 BiologicTx ® today announced their ... Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary matching ... 9 at the Miami Transplant Institute, located at Jackson ... Kidney Paired Donation (KPD) is an ... kidney transplant with one another due to incompatible blood ...
(Date:7/22/2014)... 22, 2014  PuraMed BioScience®, Inc., (OTCBB: PMBS), ... medicinal and healthcare products, announced today that the ... Aid. "We are pleased to sponsor ... CEO and Chairman of PuraMed BioScience. "Research shows ... zones experience migraines much more frequently than the ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
Cached News: